Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
Date:12/10/2007

Dr. Paul Richardson presents Phase 1 results demonstrating clinical

activity of perifosine in combination with bortezomib in patients previously treated with bortezomib, and provides an update on an ongoing

Phase 2 study of perifosine in combination with dexamethasone

NEW YORK, Dec. 10 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that positive phase 1 & phase 2 data of perifosine (KRX-0401) in patients with advanced, relapsed/refractory multiple myeloma (MM) were presented on Saturday, December 8, 2007 at the 49th Annual Meeting of the American Society of Hematology. In two separate poster presentations, Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute (DFCI) in Boston, MA, provided the phase 1 results on the clinical activity of perifosine in combination with Bortezomib, and an update on an ongoing phase 2 study of perifosine in combination with dexamethasone.

Phase 1 Perifosine + VELCADE(R) (Vel)

Poster 324-I: A MULTICENTER PHASE 1/2 TRIAL OF PERIFOSINE (KRX-0401) + BORTEZOMIB IN RELAPSED OR RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS PREVIOUSLY TREATED WITH BORTEZOMIB: PHASE I RESULTS

Eighteen patients (median age 64 yrs) with advanced MM (83% relapsed and refractory) were enrolled in one of four cohorts. Patients had a median of 5 lines of prior therapy and 100% of patients were previously treated with at least one course of therapy on bortezomib. Perifosine was escalated from 50 to 100 mg qd while bortezomib was escalated from 1.0 to 1.3 mg/mm2. No dose- limiting toxicity and no grade 3 peripheral neuropathy were reported. Toxicities were generally well
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Ohio , Aug. 28, 2014  A ... competition in generics are adding pressure to pharmaceutical, ... resources. Company resources continue to shrink and approval ... This has led companies to look for additional ... commercialization and for keeping approved products on the ...
(Date:8/28/2014)... VIEJO , Kalifornien, 28. August ... hat heute den Start der Patientenrekrutierung ... Device Exemption, Forschungsausnahmegenehmigung) zur Beurteilung der ... zur Embolisation von Aneurysmen („WEB") bekanntgegeben. Adam ... of Tennessee, Department of Neurosurgery/Semmes-Murphey Clinic, ...
(Date:8/28/2014)... , Aug. 28, 2014  Sequent Medical, ... enrollment in an Investigational Device Exemption ("IDE") pivotal ... the WEB™ Aneurysm Embolization System ("WEB"). Adam ... Department of Neurosurgery/Semmes-Murphey Clinic and Principal Investigator of ... the study, treating them with the WEB at ...
Breaking Medicine Technology:4 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 24 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 34 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 4Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 2Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 3
... Medical International Limited (NYSE: MR ), a leading ... its selected unaudited financial results for the first quarter ended ... First Quarter 2011 Net revenues were $180.9 ... 2010. Robust international sales of $108.5 million, a year-over-year ...
... /PRNewswire-Asia/ -- Chindex International, Inc. (NASDAQ: ... services in China through the operations of United Family Healthcare, ... clinics, today announced financial results for the three month period ... 2011 Financial Highlights Revenue from healthcare ...
Cached Medicine Technology:Mindray Announces First Quarter 2011 Financial Results 2Mindray Announces First Quarter 2011 Financial Results 3Mindray Announces First Quarter 2011 Financial Results 4Mindray Announces First Quarter 2011 Financial Results 5Mindray Announces First Quarter 2011 Financial Results 6Mindray Announces First Quarter 2011 Financial Results 7Mindray Announces First Quarter 2011 Financial Results 8Mindray Announces First Quarter 2011 Financial Results 9Mindray Announces First Quarter 2011 Financial Results 10Mindray Announces First Quarter 2011 Financial Results 11Mindray Announces First Quarter 2011 Financial Results 12Mindray Announces First Quarter 2011 Financial Results 13Mindray Announces First Quarter 2011 Financial Results 14Chindex International, Inc. Reports First Quarter 2011 Financial Results 2Chindex International, Inc. Reports First Quarter 2011 Financial Results 3Chindex International, Inc. Reports First Quarter 2011 Financial Results 4Chindex International, Inc. Reports First Quarter 2011 Financial Results 5Chindex International, Inc. Reports First Quarter 2011 Financial Results 6Chindex International, Inc. Reports First Quarter 2011 Financial Results 7Chindex International, Inc. Reports First Quarter 2011 Financial Results 8Chindex International, Inc. Reports First Quarter 2011 Financial Results 9Chindex International, Inc. Reports First Quarter 2011 Financial Results 10
(Date:8/28/2014)... 28, 2014 AmeriPride Services, a leading ... announced the launch of its new Customer Portal, an ... easier and more convenient for customers. The industry-leading digital ... better communicate with the company. , Features of the ... Access, download and pay bills online , ...
(Date:8/28/2014)... 2014 Clarity PSO , an ... as a federal Patient Safety Organization (PSO) for another ... Healthcare Research and Quality (AHRQ). Clarity PSO will continue ... services following the true intentions of the Patient Safety ... are proud and eager to continue our journey as ...
(Date:8/28/2014)... 2014 Genetic testing for multiple ... world, with large reference laboratories as well as ... with regard to the genetic variants analyzed, the ... struggle to find the most appropriate laboratory providers ... sort through these differences, Hayes, Inc. has added ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 veEDIS ... Emergency Department Information System (EDIS), in Lawrence Medical ... nurses and physicians to document patient care, veEDIS ... patient record-keeping, as well as the authorized, confidential ... Through the veEDIS technology, designed in accordance ...
(Date:8/28/2014)... Altec Products, Inc., a leader ... today that they have been awarded the “Partnering ... the International Association of Microsoft Channel Partners (IAMCP) ... in 1994, providing Microsoft Partners with a voice ... at large while facilitating mutual growth and business ...
Breaking Medicine News(10 mins):Health News:AmeriPride Services Launches New Customer Portal 2Health News:AmeriPride Services Launches New Customer Portal 3Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 2Health News:Clarity PSO Re-lists as a Patient Safety Organization and Continues to Advance Patient Safety 3Health News:Hayes, Inc. Unveils Laboratory Comparison Tables for GTE Clients 2Health News:veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center 2Health News:veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center 3Health News:Altec and Bond Consulting Services Receive Award from the International Association of Microsoft Channel Partners SoCal Chapter 2Health News:Altec and Bond Consulting Services Receive Award from the International Association of Microsoft Channel Partners SoCal Chapter 3
... of patients whose myelodysplastic syndrome is related to earlier ... have a poor prognosis, researchers from The University of ... Annual Meeting of the American Society of Hematology. ... or both treatments are usually told that they have ...
... of biological macromolecules are the central bases of ... cells by linking many small molecules together. Naturally ... A detailed understanding of the synthesis of these ... for understanding biological systems, and for the development ...
... smells apart is no problem for the human nose. How ... by an interdisciplinary team of researchers at the RUB. The ... of the three-dimensional structure of the binding site of an ... pattern of hydrogen bonds between odorant and receptor, which accounts ...
... News) -- Undiagnosed chronic fatigue syndrome may account for up ... for extended periods of time and are not truant or ... out of school, a new study reveals. For the ... 16 at three secondary schools in England and concluded that ...
... US Prostate Cancer Prevention Trial found cancer in many men ... which PSA level should lead to a biopsy recommendation. ... considerable controversy, that the evidence does not support recommending PSA ... the risks outweigh the benefits. Now, a study shows ...
... - Adding a drug that activates genes to frontline combination ... remission rate after initial treatment, researchers at The University of ... Meeting of the American Society of Hematology. Results of ... stage for a national Phase III clinical trial of the ...
Cached Medicine News:Health News:Prognostic model developed for MDS related to prior cancer therapy 2Health News:Prognostic model developed for MDS related to prior cancer therapy 3Health News:Visualization of DNA synthesis in vivo 2Health News:A good nose: RUB-Researchers decipher interaction of fragrances and olfactory receptors 2Health News:Chronic Fatigue Tied to Extended School Absences 2Health News:Biopsy referral after PSA screening stays consistent over time 2Health News:AML patients have high response rate with vorinostat added to treatment 2
HbA1c / HbCalibrator...
Heparin-Platelet Factor 4 Induced Antibody...
Multi-constituent Calibration Plasma for Functional Assays of Coagulation Parameters on STA© Analyzers....
Control Plasma for Assays of Unfractionated Heparins (UH) using Anti-Xa Methodon STA© Analyzers....
Medicine Products: